Variant Pharmaceuticals received its Drug Manufacturing License (DML) in 2019, marking the beginning of its journey as a pharmaceutical manufacturer. From the very start, the company focused on producing quality medicines that are safe, effective, and affordable. With a strong commitment to quality standards and patient care, Variant entered the pharmaceutical industry with the goal of making healthcare more accessible for everyone.
Soon after receiving its DML, the world was affected by the COVID-19 pandemic. Hospitals, doctors, and patients faced an urgent need for essential medicines. During this difficult time, Variant Pharmaceuticals introduced Azithromycin as its first commercial product. In the early stages of the pandemic, azithromycin was widely used by healthcare professionals around the world as part of patient management, particularly when bacterial infections were suspected or to treat secondary respiratory infections. As more scientific evidence became available, international health authorities later advised that it should not be used routinely for COVID-19 without a bacterial infection. However, during the early months of the pandemic, it played an important role in clinical practice based on the knowledge available at that time.
Variant's Azithromycin was well received by doctors because of its reliable quality, effective results, attractive packaging, and consistent availability. At a time when many medicines were difficult to find, the company worked hard to maintain a steady supply so that healthcare providers could continue treating their patients without interruption.
One of the company's biggest achievements was offering Azithromycin at an affordable price. Variant believed that quality healthcare should be available to everyone, especially during a national emergency. By keeping the price economical without compromising quality, the company helped reduce the financial burden on patients and their families while supporting doctors and hospitals across Pakistan.
The successful launch of Azithromycin during the COVID-19 pandemic became an important milestone for Variant Pharmaceuticals. It demonstrated the company's ability to respond quickly during a healthcare crisis while maintaining high standards of quality, safety, and reliability. This experience strengthened the trust of healthcare professionals and laid the foundation for Variant's continued growth as a manufacturer dedicated to improving healthcare through quality, affordable medicines.